Alternating venetoclax/azacytidine and FLT3 inhibitor treatment for NPM1- and FLT3-mutated acute myeloid leukemia

被引：2
|
作者：
Oya, Shuki [1 ]
Ozawa, Hidetoshi [1 ]
Maehiro, Yoshimi [1 ]
Nakamura, Takayuki [1 ]
Takaki, Yusuke [1 ]
Fukuyama, Toshinobu [1 ]
Yamasaki, Yoshitaka [1 ]
Yamaguchi, Maki [1 ]
Aoyama, Kazutoshi [1 ]
Mouri, Fumihiko [1 ]
Nagafuji, Koji [1 ]
机构：
[1] Kurume Univ, Dept Med, Div Hematol & Oncol, Sch Med, 67 Asahi Machi, Kurume 8300011, Japan
来源：
LEUKEMIA RESEARCH | 2023年 / 130卷
关键词：
Acute myeloid leukemia; Venetoclax; Azacytidine; FLT3; inhibitor; Nucleophosmin; Measurable residual disease; RESIDUAL DISEASE; NUCLEOPHOSMIN; CHEMOTHERAPY; VENETOCLAX;
D O I：
10.1016/j.leukres.2023.107313
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] FLT3 inhibitors in acute myeloid leukemia
    el-Shami, Khaled
    Stone, Richard M.
    Smith, B. Douglas
    EXPERT REVIEW OF HEMATOLOGY, 2008, 1 (02) : 153 - 160
  • [22] Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML
    Carter, Bing Z.
    Tao, Wenjing
    Mak, Po Yee
    Ostermann, Lauren B.
    Mak, Duncan
    McGeehan, Gerard
    Ordentlich, Peter
    Andreeff, Michael
    BLOOD, 2021, 138 (17) : 1637 - 1641
  • [23] Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse
    Ravandi, Farhad
    Kantarjian, Hagop
    Faderl, Stefan
    Garcia-Manero, Guillermo
    O'Brien, Susan
    Koller, Charles
    Pierce, Sherry
    Brandt, Mark
    Kennedy, Deborah
    Cortes, Jorge
    Beran, Miloslav
    LEUKEMIA RESEARCH, 2010, 34 (06) : 752 - 756
  • [24] Idarubicin and cytarabine with and without midostaurin for FLT3-mutated acute myeloid leukemia
    Diebold, Kendall
    Bourne, Garrett
    Espinoza-Gutarra, Manuel
    Al-Kadhimi, Zaid
    Bachiashvili, Kimo
    Rangaraju, Sravanti
    Vachhani, Pankit
    Bhatia, Ravi
    Jamy, Omer
    LEUKEMIA & LYMPHOMA, 2024, 65 (11) : 1737 - 1739
  • [25] Combined treatment with venetoclax, dasatinib, and FLT3 inhibitors for NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia: A pediatric case report
    Wen, Xiaojia
    Wu, Ying
    Huang, Pengli
    Zheng, Huyong
    PEDIATRIC BLOOD & CANCER, 2023, 70 (07)
  • [26] Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation
    Chew, Serena
    Mackey, Melissa C.
    Jabbour, Elias
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [27] Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells
    Chen, Fangli
    Ishikawa, Yuichi
    Akashi, Akimi
    Naoe, Tomoki
    Kiyoi, Hitoshi
    ONCOTARGET, 2016, 7 (30) : 47018 - 47032
  • [28] FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics
    Lei Wang
    Wei-lai Xu
    Hai-tao Meng
    Wen-bin Qian
    Wen-yuan Mai
    Hong-yan Tong
    Li-ping Mao
    Yin Tong
    Jie-jing Qian
    Yin-jun Lou
    Zhi-mei Chen
    Yun-gui Wang
    Jie Jin
    Journal of Zhejiang University SCIENCE B, 2010, 11 : 762 - 770
  • [29] FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics
    Wang, Lei
    Xu, Wei-lai
    Meng, Hai-tao
    Qian, Wen-bin
    Mai, Wen-yuan
    Tong, Hong-yan
    Mao, Li-ping
    Tong, Yin
    Qian, Jie-jing
    Lou, Yin-jun
    Chen, Zhi-mei
    Wang, Yun-gui
    Jin, Jie
    JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B, 2010, 11 (10): : 762 - 770
  • [30] Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis
    Sly, Nichole
    Gaspar, Katie
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2019, 76 (05) : 268 - 274
12345